Concepts (55)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 4 | 2024 | 1019 | 0.560 |
Why?
|
| Antimalarials | 2 | 2020 | 64 | 0.560 |
Why?
|
| Curcumin | 2 | 2020 | 118 | 0.520 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 187 | 0.510 |
Why?
|
| Butyrates | 1 | 2019 | 34 | 0.300 |
Why?
|
| Histone Deacetylases | 1 | 2019 | 61 | 0.290 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 184 | 0.290 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2019 | 140 | 0.280 |
Why?
|
| Pterocarpans | 1 | 2017 | 25 | 0.260 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 75 | 0.240 |
Why?
|
| Ethers | 1 | 2016 | 21 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 39 | 0.230 |
Why?
|
| Protein Kinases | 1 | 2015 | 100 | 0.220 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 134 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 159 | 0.210 |
Why?
|
| Hydrogen Sulfide | 1 | 2023 | 77 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 218 | 0.170 |
Why?
|
| Signal Transduction | 1 | 2019 | 2157 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2025 | 460 | 0.150 |
Why?
|
| Alzheimer Disease | 1 | 2025 | 1001 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 1092 | 0.120 |
Why?
|
| Molecular Structure | 2 | 2020 | 570 | 0.120 |
Why?
|
| Structure-Activity Relationship | 2 | 2016 | 506 | 0.100 |
Why?
|
| Animals | 5 | 2025 | 16992 | 0.100 |
Why?
|
| Drug Delivery Systems | 2 | 2025 | 277 | 0.090 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2019 | 91 | 0.070 |
Why?
|
| Humans | 6 | 2025 | 43102 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 299 | 0.060 |
Why?
|
| Computer-Aided Design | 1 | 2016 | 11 | 0.060 |
Why?
|
| Allosteric Regulation | 1 | 2016 | 27 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 99 | 0.060 |
Why?
|
| Molecular Conformation | 1 | 2016 | 155 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2019 | 1621 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 127 | 0.060 |
Why?
|
| Crystallography, X-Ray | 1 | 2015 | 280 | 0.060 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2016 | 110 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2015 | 108 | 0.050 |
Why?
|
| Ligands | 1 | 2015 | 388 | 0.050 |
Why?
|
| tau Proteins | 1 | 2025 | 186 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2025 | 173 | 0.050 |
Why?
|
| Sulfides | 1 | 2023 | 78 | 0.050 |
Why?
|
| Swine | 1 | 2023 | 212 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1455 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2024 | 94 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 182 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1124 | 0.050 |
Why?
|
| Protein Binding | 1 | 2016 | 1082 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2015 | 876 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2023 | 465 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 241 | 0.040 |
Why?
|
| Rats | 1 | 2019 | 3735 | 0.040 |
Why?
|
| Apoptosis | 1 | 2019 | 1568 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 307 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 1081 | 0.040 |
Why?
|
| Male | 1 | 2016 | 23409 | 0.020 |
Why?
|